Total Payments
$3,749
2024 Payments
$496.53
Companies
31
Transactions
214
Medicare Patients
41,710
Medicare Billing
$3.8M
Payment Breakdown by Category
Food & Beverage$3,749 (100.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $3,749 | 214 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $394.67 | 34 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $349.12 | 15 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $333.54 | 25 | $0 (2024) |
| Merck Sharp & Dohme LLC | $269.71 | 17 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $241.17 | 17 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $228.70 | 12 | $0 (2024) |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $225.52 | 15 | $0 (2023) |
| Amgen Inc. | $207.37 | 13 | $0 (2024) |
| ATRICURE, INC. | $201.25 | 2 | $0 (2021) |
| iRhythm Technologies, Inc. | $196.66 | 7 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $496.53 | 23 | AstraZeneca Pharmaceuticals LP ($97.42) |
| 2023 | $501.09 | 32 | Novartis Pharmaceuticals Corporation ($130.88) |
| 2022 | $737.35 | 44 | Boehringer Ingelheim Pharmaceuticals, Inc. ($206.98) |
| 2021 | $454.69 | 19 | Abbott Laboratories ($106.34) |
| 2020 | $212.55 | 9 | ATRICURE, INC. ($102.18) |
| 2019 | $556.18 | 36 | PFIZER INC. ($108.12) |
| 2018 | $466.11 | 30 | iRhythm Technologies, Inc. ($132.21) |
| 2017 | $324.09 | 21 | Amgen Inc. ($85.17) |
All Payment Transactions
214 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/22/2024 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 10/10/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Genetic Disease | ||||||
| 10/04/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.95 | General |
| Category: Genetic Disease | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: Obesity | ||||||
| 07/29/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: Cardiology | ||||||
| 07/26/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $23.48 | General |
| Category: LUX-Dx_CRM | ||||||
| 07/11/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Genetic Disease | ||||||
| 07/10/2024 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $14.38 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/20/2024 | ABIOMED | Impella (Device) | Food and Beverage | Cash or cash equivalent | $32.70 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 06/17/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 05/09/2024 | Daxor Corporation | BVA-100 (Device) | Food and Beverage | Cash or cash equivalent | $41.15 | General |
| Category: Diagnostic Test | ||||||
| 04/22/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Cardiology | ||||||
| 04/17/2024 | Nuwellis, Inc. | Aquadex Smartflow Console (Device) | Food and Beverage | Cash or cash equivalent | $19.92 | General |
| Category: Cardiology | ||||||
| 04/05/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $14.94 | General |
| 03/12/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/08/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $18.04 | General |
| Category: CARDIOVASCULAR | ||||||
| 02/15/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $13.61 | General |
| Category: Cardiology | ||||||
| 02/09/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: Genetic Disease | ||||||
| 02/02/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $15.17 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 01/26/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $24.04 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/23/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $60.38 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/08/2023 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $14.39 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/25/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $15.79 | General |
| Category: Cardiology/Vascular Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 75 | 9,147 | 26,173 | $4.1M | $861,074 |
| 2022 | 77 | 11,024 | 34,455 | $5.2M | $1.1M |
| 2021 | 75 | 10,287 | 25,747 | $4.8M | $950,258 |
| 2020 | 77 | 11,252 | 29,170 | $4.8M | $953,467 |
Total Patients
41,710
Total Services
115,545
Medicare Billing
$3.8M
Procedure Codes
320
All Medicare Procedures & Services
320 procedure records from CMS Medicare Utilization — Page 1 of 13
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 133 | 133 | $366,324 | $138,001 | 37.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 904 | 1,169 | $187,040 | $96,060 | 51.4% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 749 | 751 | $833,121 | $95,662 | 11.5% |
| 78452 | Nuclear medicine studies of heart muscle at rest and with stress and spect | Office | 2023 | 328 | 328 | $579,017 | $85,117 | 14.7% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 135 | 136 | $297,000 | $65,071 | 21.9% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 315 | 1,260 | $109,620 | $57,100 | 52.1% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 16 | 4,544 | $59,072 | $41,813 | 70.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 451 | 462 | $226,842 | $22,128 | 9.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 173 | 173 | $101,205 | $21,199 | 20.9% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 453 | 454 | $176,152 | $20,574 | 11.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 175 | 175 | $43,050 | $18,940 | 44.0% |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | Office | 2023 | 269 | 280 | $98,992 | $16,477 | 16.6% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 313 | 337 | $55,614 | $16,312 | 29.3% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 18 | 338 | $33,124 | $9,441 | 28.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 822 | 924 | $83,160 | $8,769 | 10.5% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 114 | 114 | $63,042 | $8,711 | 13.8% |
| 75574 | Ct scan of blood vessels and grafts of heart with contrast | Office | 2023 | 41 | 41 | $108,896 | $8,116 | 7.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 74 | 120 | $16,920 | $7,034 | 41.6% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 361 | 378 | $40,446 | $7,025 | 17.4% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 475 | 493 | $49,300 | $6,431 | 13.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 18 | 184 | $22,448 | $6,136 | 27.3% |
| 93284 | Programming of multiple lead implantable defibrillator system | Office | 2023 | 79 | 83 | $21,403 | $5,276 | 24.7% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 18 | 164 | $24,108 | $5,223 | 21.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 40 | 58 | $11,716 | $5,074 | 43.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 41 | 41 | $9,225 | $5,051 | 54.8% |
About Dr. William Calhoun, MD
Dr. William Calhoun, MD is a Cardiovascular Disease healthcare provider based in Tupelo, Mississippi. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/30/2006. The National Provider Identifier (NPI) number assigned to this provider is 1932219177.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Calhoun, MD has received a total of $3,749 in payments from pharmaceutical and medical device companies, with $496.53 received in 2024. These payments were reported across 214 transactions from 31 companies. The most common payment nature is "Food and Beverage" ($3,749).
As a Medicare-enrolled provider, Calhoun has provided services to 41,710 Medicare beneficiaries, totaling 115,545 services with total Medicare billing of $3.8M. Data is available for 4 years (2020–2023), covering 320 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Location Tupelo, MS
- Active Since 08/30/2006
- Last Updated 07/12/2019
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1932219177
Products in Payments
- JARDIANCE (Drug) $436.22
- VERQUVO (Drug) $269.71
- XARELTO (Drug) $241.17
- LifeVest (Device) $225.52
- ELIQUIS (Drug) $220.23
- CHANTIX (Drug) $185.83
- ENTRESTO (Drug) $180.46
- ZIO Patch (Device) $164.03
- LEQVIO (Drug) $153.08
- Repatha (Biological) $132.38
- MitraClip System (Device) $106.34
- FARXIGA (Drug) $103.24
- ATRICURE CRYOSURGICAL SYSTEM (Device) $102.18
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) $99.07
- WAINUA (Drug) $97.42
- PRALUENT (Drug) $96.07
- ONPATTRO (Drug) $86.04
- VYNDAQEL (Drug) $81.19
- AMVUTTRA (Drug) $77.32
- Corlanor (Drug) $74.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Tupelo
Barry Bertolet, Md, MD
Cardiovascular Disease — Payments: $525,866
Cardiovascular Disease $525,866
James Stone, M.d, M.D
Cardiovascular Disease — Payments: $120,310
Cardiovascular Disease $120,310
Dr. Michael Boler, D.o, D.O
Cardiovascular Disease — Payments: $7,154
Cardiovascular Disease $7,154
Roger Williams, Md, MD
Cardiovascular Disease — Payments: $7,109
Cardiovascular Disease $7,109
Dr. Benjamin Blossom, M.d, M.D
Cardiovascular Disease — Payments: $6,791
Cardiovascular Disease $6,791
Joseph Adams, Md, MD
Cardiovascular Disease — Payments: $4,212
Cardiovascular Disease $4,212